<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335591</url>
  </required_header>
  <id_info>
    <org_study_id>19-OBE2109-006</org_study_id>
    <nct_id>NCT04335591</nct_id>
  </id_info>
  <brief_title>Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)</brief_title>
  <official_title>A Double-blind Randomized Extension Study to Assess the Long-term Efficacy and Safety of Linzagolix in Subjects With Endometriosis-associated Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ObsEva SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ObsEva SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this extension study is to assess the maintenance of efficacy of
      linzagolix administered orally once daily for up to an additional 6 months (for up to 12
      months of treatment in total) in women who have already completed 6 months of linzagolix
      treatment at a dose of 75 mg alone or of 200 mg in combination with ABT (E2 1 mg / NETA 0.5
      mg), in the management of moderate to severe endometriosis-associated pain (EAP) in women
      with surgically confirmed endometriosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, double-blind study. Subjects who have completed the
      6-month Treatment Period in 18-OBE2109-003 - Edelweiss 3 study (herein referred to as main
      study) will be invited to enter the present extension study. Month 6 visit of the main study
      is a decision point for Subjects to either end treatment and enter a post-treatment follow up
      (part of the main study), or to opt for a 6-month treatment extension.

      All subjects will receive once daily either linzagolix 75 mg alone (with ABT placebo) or 200
      mg combined with ABT for 6 months. Subjects who received placebo during the main study will
      be randomized to either linzagolix 75 mg alone (with ABT placebo) or linzagolix 200 mg with
      ABT. Subjects who received active treatment during the main study will continue with the same
      treatment. Double-dummy design will be used in order to maintain the blinding of the study.

      After end of treatment in the extension study (6-month treatment period: from Month 6 to
      Month 12), subjects will enter a post-treatment Follow-Up Period of 6 months with no
      investigational medicinal product (IMP) or - for subjects willing to continue treatment - a
      second extension study will be proposed.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 5, 2020</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dysmenorrhea</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change at Month 12 from baseline in the mean daily assessment of dysmenorrhea measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-menstrual pelvic pain</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change at Month 12 from baseline in the mean daily assessment of non-menstrual pelvic pain measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dysmenorrhea</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change from baseline to Month 12 in dysmenorrhea measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-menstrual pelvic pain</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change from baseline to Month 12 in non-menstrual pelvic pain measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyschezia</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change from baseline to Month 12 in dyschezia measured on a 0-10 Numeric Rating Scale (NRS) using an electronic diary. The lower value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Pelvic Pain</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change from baseline to Month 12 in overall pelvic pain measured on a 0-10 Numeric Rating Scale (NRS) using an electronic diary. The lower value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interference of pain with the ability to perform daily activities</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change from baseline to Month 12 in the interference of pain with the ability to perform daily activities, measured using the pain dimension of the Endometriosis Health Profile-30 (EHP-30) using an electronic diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspareunia</measure>
    <time_frame>Baseline to Month 12</time_frame>
    <description>Change from baseline to Month 12 in dyspareunia measured on a 0-3 Verbal Rating Scale (VRS) using an electronic diary. The lower value represents a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No analgesic use for endometriosis associated pain</measure>
    <time_frame>During the preceding 4-week period at each scheduled assessment</time_frame>
    <description>Proportion of subjects reporting no analgesic use for endometriosis associated pain, during the preceding 4-week period at each scheduled assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>No opiate use for endometriosis associated pain</measure>
    <time_frame>During the preceding 4-week period at each scheduled assessment</time_frame>
    <description>Proportion of subjects reporting no opiate use for endometriosis associated pain, during the preceding 4-week period at each scheduled assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>75 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>200 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet to match 75 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet to match 200 mg linzagolix tablet</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Add-back capsule (E2 1 mg / NETA 0.5 mg)</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 200 mg + Add-back (E2 1 mg / NETA 0.5 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule to match Add-back capsule</intervention_name>
    <description>For oral administration once daily</description>
    <arm_group_label>Linzagolix 75 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The subject must have:

          -  completed the 6-month treatment in the main study.

          -  agree to continue to use only the analgesic rescue medication permitted by the
             protocol during the Treatment and Follow-up Periods.

          -  To continue to comply with the requirements of the study protocol for the duration of
             the extension study.

        Exclusion Criteria:

        The subject will be excluded if she:

          -  Is pregnant or breast feeding or is planning a pregnancy within the duration of the of
             the study (including the Follow-up Period).

          -  likely to require treatment during the study with any of the restricted medications

          -  has any other clinically significant gynecologic condition identified during the main
             study on transvaginal ultrasound (TVUS), on endometrial biopsy or at the manual breast
             examination, which might interfere with the study efficacy and safety objectives.

          -  met any of the main study discontinuation criteria
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females Only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Achieve Clinical Research/ ID # 601</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Choice Research, LLC/ ID # 609</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Clinical Research/ ID # 618</name>
      <address>
        <city>Chiefland</city>
        <state>Florida</state>
        <zip>32626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universal Axon - Homestead, LLC/ ID # 620</name>
      <address>
        <city>Homestead</city>
        <state>Florida</state>
        <zip>33030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multi-Specialty Research Associates, Inc./ ID # 625</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellington Anti-Aging, LLC/ ID # 613</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <zip>33470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedman Clinical Trials/ ID # 612</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Specialty Research/ ID # 610</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>83687</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's &amp; Family Care, LLC dba GTC Research/ ID # 608</name>
      <address>
        <city>Shawnee Mission</city>
        <state>Kansas</state>
        <zip>66218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Clinical Research / ID # 611</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Women's Health &amp; Wellnes/ ID # 603</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington/ ID # 614</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UWCR - Lyndhurst Clinical Researc/ ID# 605</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obstetrics &amp; Gynecology Associates, Inc./ ID# 606</name>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <zip>45014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Main Line Fertility Center/ ID # 604</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Medical Research LLC/ ID# 602</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Storks Research, LLC/ ID # 623</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanner Clinic/ ID # 624</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Avis-Medica/ ID # 134</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Sliven/ ID # 131</name>
      <address>
        <city>Sliven</city>
        <zip>8800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Centre Excelsior /ID # 135</name>
      <address>
        <city>Sofia</city>
        <zip>1407</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Practice for Specialized Medical Assistance in GINART/ ID # 132</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment St. Sofia/ ID # 137</name>
      <address>
        <city>Sofia</city>
        <zip>1618</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Doverie / ID # 136</name>
      <address>
        <city>Sofia</city>
        <zip>1632</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment &quot;Sofiamed&quot;/ ID # 133</name>
      <address>
        <city>Sofia</city>
        <zip>1797</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Principal SMO Kft/ ID # 250</name>
      <address>
        <city>Baja</city>
        <state>Bacs-Kiskun</state>
        <zip>6500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Róbert Károly Magánkórház/ ID # 253</name>
      <address>
        <city>Budapest</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szent Anna Szuleszeti-Nogyogyaszati/ ID # 251</name>
      <address>
        <city>Debrecen</city>
        <zip>4024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mediroyal Prevencios Kozpont/ ID # 252</name>
      <address>
        <city>Kecskemét</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borsod-Abauj-Zemplen Megyei Kozponti Korhaz/ ID # 254</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ / ID # 255</name>
      <address>
        <city>Szeged</city>
        <zip>6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lubelskie Centrum Diagnostyczne/ ID # 402</name>
      <address>
        <city>Świdnik</city>
        <state>Lubelskie</state>
        <zip>21-040</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prywatna Klinika Ginekologiczno - Położnicza/ ID # 404</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15-224</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska Krzysztof Wilk/ ID # 411</name>
      <address>
        <city>Katowice</city>
        <zip>40-301</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Medical Research sp. Z o. O/ ID # 406</name>
      <address>
        <city>Katowice</city>
        <zip>40-628</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zrowotnej GynCentrum/ ID # 407</name>
      <address>
        <city>Katowice</city>
        <zip>40-851</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indywidualna Specjalistyczna Praktyka Lekarska Maciej Żymła/ ID # 412</name>
      <address>
        <city>Knurów</city>
        <zip>44-190</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kotarski Jan Specjalistyczny Gabinet Ginekologiczno Polozniczy/ ID # 405</name>
      <address>
        <city>Lublin</city>
        <zip>20-064</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Chodźki Lublin/ ID # 403</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VITA LONGA Sp. z o.o./ ID # 408</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Ginekologii Endokrynologii i Medycyny Rozrodu &quot;Artemida&quot;/ ID # 409</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-357</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu/ ID # 410</name>
      <address>
        <city>Przemyśl</city>
        <zip>37-700</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczny Gabinet Lekarski Krzysztof Dynowski / ID # 401</name>
      <address>
        <city>Warsaw</city>
        <zip>02-929</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Dexeus/ ID # 306</name>
      <address>
        <city>Barcelona</city>
        <zip>8028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica IVI Bilbao/ ID # 305</name>
      <address>
        <city>Leioa</city>
        <zip>39004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz/ ID # 301</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Reina Sofia/ ID # 304</name>
      <address>
        <city>Murcia</city>
        <zip>30003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga/ ID # 303</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consorci Hospital General Universitari Valencia/ ID # 302</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dysmenorrhea</keyword>
  <keyword>Dyspareunia</keyword>
  <keyword>Dyschezia</keyword>
  <keyword>Non-menstrual pelvic pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

